Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Given the potency enhancing effect of the
2020-12-09

Given the potency enhancing effect of the 4--butyl group, this substitution was incorporated into the Eastern portion of the molecule for further SAR investigations (). Removal of the phenol group (SR19822) or moving it from the -position to the -position (SR19552) or led to significant loss of acti
-
The underlying assumption of consolidation re
2020-12-09

The underlying assumption of consolidation/re-consolidation is that the FAK Inhibitor 14 synthesis activity initiated during the acquisition trial/re-consolidation trial continues to persist briefly after completion of the trial and it is during this post-trial period that immediate post-trial treat
-
br Chemistry The test compounds listed
2020-12-09

Chemistry The test compounds listed in Table 1, Table 2, Table 3, Table 4, Table 5, were synthesized as outlined in Scheme 1, Scheme 2, Scheme 3, Scheme 4, Scheme 5. Synthesis of 2–5 is described in Scheme 1. N-Sulfonylation of the aniline 26 with benzenesulfonyl chloride afforded the sulfonamide
-
br Experimental procedures br Acknowledgments br Introductio
2020-12-09

Experimental procedures Acknowledgments Introduction Receptor tyrosine kinases (RTKs) control many fundamental cellular processes, such as cell proliferation, differentiation, migration, and metabolism (Lemmon and Schlessinger, 2010). RTK activity is normally tightly controlled, and dysregu
-
Imatinib STI is a first line tyrosine kinase inhibitor TKI
2020-12-09

Imatinib (STI-571) is a first-line tyrosine kinase inhibitor (TKI) targeted at breakpoint cluster region-Abelson kinase (ABL) for the treatment of chronic myeloid leukemia (CML) [26]. As a type II inhibitor, imatinib achieves significant selectivity by binding to an inactive DFG-out conformation (DF
-
There is evidence that the response
2020-12-09

There is evidence that the response of CYP450 activity to DEX is species-specific. CYP1A and CYP3A expressions were strongly induced by DEX in porcine hepatocytes (Rasmussen et al., 2014) and in rat and human, but not minipig or beagle dog hepatocytes (Lu and Li, 2001). Within fish, there are also s
-
Lymphocyte mobility and homing is modulated by the chemoattr
2020-12-09

Lymphocyte mobility and homing is modulated by the chemoattractant receptor subfamily of G protein-coupled receptors (GPCRs) (Campbell et al., 2003, Rot and von Andrian, 2004). B cell migration and position are controlled to a large extent by the lymphoid chemokines CXCL13, CXCL12, CCL19, and CCL21
-
br Materials and methods br Results br Discussion
2020-12-08

Materials and methods Results Discussion Plg plays important roles in various physiological processes, such as fibrinolysis, proteolysis, cell migration, differentiation, tissue remodeling, and inflammation [6], [7], [8]. We herein found that Plg deficiency enhanced insulin secretion, and w
-
phosphodiesterase As DNA methylation plays a critical role i
2020-12-08

As DNA methylation plays a critical role in organismic development and human diseases, the interest in DNA methyltransferases is constantly increasing. Extensive studies on the repertoires of dnmts genes have indicated increasing dnmts members in eukaryotes (Goll and Bestor, 2005; Ponger and Li, 200
-
We then undertook computational studies that suggest the
2020-12-08

We then undertook computational studies that suggest the cyanobacterial ALDH (and planctomyces ALDH) represent the evolutionary ancestor of human and other eukaryotic ALDH1/2 given that cfALDH contains signature residues matching both the human proteins throughout the surface of the protein and the
-
The second DDR binding partner identified here Shp
2020-12-08

The second DDR1-binding partner identified here, Shp-2, which was not found in the two-hybrid screen but using a bioinformatics approach, is also a mediator of cell migration. Since Shp-2 has two SH2 domains, as well as phosphotyrosine phosphatase enzymatic activity and two C-terminal tyrosines targ
-
br Materials and methods br Acknowledgments br
2020-12-08

Materials and methods Acknowledgments Introduction Proton pumps convert the energy of high-energy compounds into the (+)-Apogossypol of protons across biomembranes. They play two physiological roles: pH regulation and the formation of proton-motive forces in their membranes. The simplest o
-
Both anxiogenic and antinociceptive effects produced by
2020-12-08

Both anxiogenic and antinociceptive effects produced by CRF seem to be selective for the CRF1 receptor, since intra-dPAG microinjection of ASV 30, a CRF2 receptor antagonist, altered neither the anxiety nor the antinociception response. Intra-dPAG ASV 30 was also unable to prevent the anxiogenic (ob
-
Unexpectedly CRF receptor agonist and antagonist evoked simi
2020-12-08

Unexpectedly, CRF2 receptor agonist and antagonist evoked similar effects in the fall in tail skin temperature caused by restraint. However, Ucn3 reduced basal values of tail skin temperature, thus indicating that some degree of basal vasoconstriction caused by BNST treatment with Ucn3 may have cont
-
br Method Detailed study protocol
2020-12-07

Method Detailed study protocol was reported previously. The ULTIMATE- HFrEF trial was approved by the Institutional Review Board of our hospital, and the study drug, udenafil, was approved as Investigational New Drug for treatment in patients with chronic HFrEF by Ministry of Food and Drug Safety
16140 records 774/1076 page Previous Next First page 上5页 771772773774775 下5页 Last page